Ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
Janssen
['cilta-cel']
adverse events / toxicity:
- higher rates of covid deaths / tox deaths in cilta-cel arm
- 76% crs but only 1% grade 3/4 crs
-4.5% icans but zero grade 3/4 icans
- interestingly 16 (9%) cranial nerve palsies
- 27% g3/4 infections vs 25% in soc #asco23 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem